Conclusions from the Committee for Medicinal Products for Human Use (CHMP) – Review of safety of erythropoiesis stimulating agents (ESAs) in patients with anaemia resulting from renal insufficiency or chemotherapy in cancer patients. 2008 - Medicines and Healthcare products Regulatory Agency (MHRA)
. Accessed May 2, 2012